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Abstract
Background: Despite its biologic plausibility, the association between liver function and mortality
of patients with chronic liver disease is not well supported by data. Therefore, we examined
whether the galactose elimination capacity (GEC), a physiological measure of the total metabolic
capacity of the liver, was associated with mortality in a large cohort of patients with newly-
diagnosed cirrhosis.
Methods: By combining data from a GEC database with data from healthcare registries we
identified cirrhosis patients with a GEC test at the time of cirrhosis diagnosis in 1992–2005. We
divided the patients into 10 equal-sized groups according to GEC and calculated all-cause mortality
as well as cirrhosis-related and not cirrhosis-related mortality for each group. Cox regression was
used to adjust the association between GEC and all-cause mortality for confounding by age, gender
and comorbidity, measured by the Charlson comorbidity index.
Results: We included 781 patients, and 454 (58%) of them died during 2,617 years of follow-up.
Among the 75% of patients with a decreased GEC (<1.75 mmol/min), GEC was a strong predictor
of 30-day, 1-year, and 5-year mortality, and this could not be explained by confounding (crude
hazard ratio for a 0.5 mmol/min GEC increase = 0.74, 95% CI 0.59–0.92; adjusted hazard ratio =
0.64, 95% CI 0.51–0.81). Further analyses showed that the association between GEC and mortality
was identical for patients with alcoholic or non-alcoholic cirrhosis etiology, that it also existed
among patients with comorbidity, and that GEC was only a predictor of cirrhosis-related mortality.
Among the 25% of patients with a GEC in the normal range (≥ 1.75 mmol/min), GEC was only
weakly associated with mortality (crude hazard ratio = 0.79, 95% CI 0.59–1.05; adjusted hazard
ratio = 0.80, 95% CI 0.60–1.08).
Conclusion: Among patients with newly-diagnosed cirrhosis and a decreased GEC, the GEC was
a strong predictor of short- and long-term all-cause and cirrhosis-related mortality. These findings
support the expectation that loss of liver function increases mortality.
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Background
Cirrhosis is a chronic liver disease with high mortality [1].
The condition implies a loss of liver function, and it is a
fundamental assumption that the extent of this loss is
important for survival. Still, little is known about the asso-
ciation between the prognosis of the patients and their
liver function. Clinicians therefore often use scores based
on standard blood chemistry tests and clinical signs of
liver disease, such as the Child-Pugh score and the MELD-
score, as prognostic indicators [2]. However, these scores
reflect symptoms and complications of the liver disease,
not the liver function as such.
The carbohydrate galactose is metabolized nearly exclu-
sively in the liver, and the elimination rate at blood con-
centrations high enough to yield near-saturated
enzymatic conversion, the galactose elimination capacity
(GEC), is used as a quantitative measure of the metabolic
capacity of the liver. GEC is assumed to reflect the liver's
total capacity to serve the vitally important metabolic
homeostasis of the organism [3,4].
A number of studies support the concept that the meta-
bolic capacity of the liver, as measured with the GEC, is
associated with mortality of cirrhosis patients: A prognos-
tic value of the test was documented in patients with acute
liver failure [5], and studies of cirrhosis patients found
that the GEC added prognostic information beyond that
obtained by standard blood chemistry tests [6-9],
although this was not a consistent finding [10-12]. These
studies, however, included only selected cirrhosis
patients; comprised an insufficient number of patients
(between 35 and 194); had relatively short observation
time; and aimed to examine the utility of including the
GEC in clinical prediction rules, not its association with
mortality [6-12]. Thus the concept of an association
between GEC and mortality of cirrhosis patients remains
unproven despite its biologic plausibility. The association
is best examined in a large cohort of cirrhosis patients
with wide variation in GEC, and neither the inclusion cri-
teria nor the analysis should include possible correlates of
GEC, such as standard blood chemistry tests or clinical
signs of liver failure [13]. Furthermore, an analysis of the
association between GEC and mortality should adjust for
age and gender because the GEC declines with age and is
higher in men than in women [14-16], and it should also
adjust for comorbidity that has a considerable impact on
mortality [17]. We have available a sufficiently large and
well-defined patient material to conduct such an analysis:
781 Danish patients with newly-diagnosed cirrhosis fol-
lowed for up to 13 years.
Methods
According to Danish law, studies that are based exclu-
sively on data from administrative registries and clinical
databases, such as this, require neither ethical approval
nor patient consent.
Study population
The study was based on GEC tests done between 1 August
1992 and 31 December 2005 in the two Danish tertiary
referral centers for liver disease. All tests were performed
as previously described [18,19]: A galactose solution is
injected intravenously over 5 minutes (1 ml/kg body
weight of a 500 mg/ml galactose solution), arterialized
capillary blood is sampled every 5 minutes from 20 to 45
minutes to measure blood concentration of galactose, and
urine is collected for 4 hours to measure urinary excretion
of galactose. The GEC is calculated from the injected
amount minus the excreted amount and from the straight
line connecting the observations of blood galactose con-
centration against time:
where 'injected' is the amount of galactose administered,
'excreted' is the amount excreted in the urine, 'timeconc = o'
is the time at which the blood galactose concentration
would theoretically reach zero, and 7 minutes a correction
for delay of galactose equilibration between extra- and
intravascular spaces.
The average GEC values in men and women without liver
disease are 2.7 (95% CI 1.7–3.6) and 2.4 (95% CI 1.4–
3.4) mmol/min, respectively [16]. No other quantitative
liver function test was systematically performed.
We identified 3388 patients with a GEC test, among
whom 781 had been diagnosed with cirrhosis less than 90
days before their first test, according to hospital discharge
diagnoses recorded in the Danish National Patient Regis-
try. This registry records individual-level information
from all admissions to Danish hospitals since 1977, and
from all outpatient visits since 1995 [20]. The informa-
tion includes primary and secondary discharge diagnoses
coded according to ICD8 (before 1994) or ICD10 (from
1994), and we defined cirrhosis by the following codes:
571.09, 571.92, 571.99, K70.3, and K74.6. Comorbid dis-
eases were identified in the same registry and defined by
the Charlson comorbidity index, based on 19 common
chronic diseases, as previously described [17,21].
Statistical analysis
The patients were followed from their first GEC test until
death or 31 December 2005. Dates of death were obtained
from the Danish Civil Registration System [22].
Cumulative mortality
The cumulative mortality was estimated as the comple-
ment of the Kaplan-Meier estimate of survival probability.
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We examined whether GEC was a predictor of mortality
by dividing the patients into 10 equal-sized groups
according to GEC (i.e., GEC-deciles) and plotting each
decile's median GEC against its 30-day, 1-year, and 5-year
mortality. We used lowess smoothing to facilitate the vis-
ual interpretation of the plots [23].
Cox proportional hazards regression
In order to examine whether the association between GEC
and mortality was confounded, we estimated the hazard
ratio associated with a 0.5 mmol/min GEC increase before
and after adjustment for gender, age at GEC test, and pres-
ence of comorbidity (defined by a Charlson comorbidity
index of 1 or higher). Based on the analysis of cumulative
mortality we conducted separate analyses for patients
with a GEC <1.75 mmol/min (decreased liver function) or
≥1.75 mmol/min. Among patients with a GEC below 1.75
mmol/min, the Cox regression model violated the
assumption of proportional hazards, but this violation
was of no consequence because the model still yielded the
average hazard ratio during follow-up [24], and that was
sufficient to examine the impact of confounding.
Cirrhosis-related mortality
In Denmark, cause(s) of death are immediately reported
by the attending physician to the Danish Cause of Death
Registry. We used data from the registry to compute the
cumulative incidence of cirrhosis-related death and of
death from other causes [25]. Cirrhosis-related death was
defined as having cirrhosis, liver failure, or variceal bleed-
ing as a cause of death; all other deaths were classified as
not cirrhosis-related. In this analysis, cirrhosis patients
were censored on 31 December 2001 because cause of
death-registration was incomplete after 2001. The analy-
ses were repeated with restriction to patients with alco-
holic cirrhosis (diagnosis codes 571.09 or K70.3), non-
alcoholic cirrhosis, or cirrhosis with comorbidity.
Results
Among the 781 patients, 454 (58%) died during follow-
up. The total observation time was 2,617 years with a
median of 2.5 years per patient and a maximum of 13.3
years. The median age at inclusion was 52 years and 65%
were men. GEC ranged from 0.59 to 3.97 mmol/min
(median 1.48 mmol/min). The GEC was not associated
with age, but it was higher in men than in women
(median GEC 1.54 vs. 1.40 mmol/min) and in the 29% of
patients with comorbidity (median GEC 1.57 vs. 1.45
mmol/min). The most prevalent comorbidities were dia-
betes (9% of patients at inclusion), ulcer disease (9%),
and atherosclerosis-related disease (8%), which collec-
tively comprised 78% of all comorbidity.
GEC was a strong predictor of short- and long-term mor-
tality, particularly among the 75% of patients with a GEC
below 1.75 mmol/min (Figure 1). For example, patients
with a GEC of 1.75 mmol/min had a lower mortality than
patients with a GEC of 1.25 mmol/min: 5% vs. 14% after
30 days, 22% vs. 35% after 1 year, and 48% vs. 61% after
5 years (Figure 1), and adjustment for potential con-
founders strengthened the GEC-mortality association
(crude hazard ratio = 0.74, 95% CI 0.59–0.92; adjusted
hazard ratio = 0.64, 95% CI 0.51–0.81), primarily because
male gender was a risk factor for death and also associated
with a high GEC (Table 1). Among the patients with a
GEC above 1.75 mmol/min, the association between GEC
and mortality was weaker and unaffected by confounding
(crude hazard ratio = 0.79, 95% CI 0.59–1.05; adjusted
hazard ratio = 0.80, 95% CI 0.60–1.08) (Figure 1 and
Table 1).
The mortality was similar for patients with alcoholic cir-
rhosis (76% of patients) or non-alcoholic cirrhosis, and
GEC had the same association with mortality in both
groups. Furthermore, the GEC-mortality association was
also present among the cirrhosis patients who had comor-
bidities.
All-cause mortality after 30 days, 1 year, and 5 years by GEC  for the 781 included cirrhosis patients Figure 1
All-cause mortality after 30 days, 1 year, and 5 years 
by GEC for the 781 included cirrhosis patients. The 
gray lines connect each GEC-decile's median GEC with its 
observed mortality, and the black lines are lowess smooth-
ings of the gray lines.
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Of the 587 patients who were available for the analysis of
causes of death, 275 (47%) died during follow-up, 219
(80%) from cirrhosis-related causes and 56 (20%) from
other causes. Irrespective of GEC, the risk of cirrhosis-
related death exceeded the risk of death from other causes.
The GEC was clearly a predictor of the risk of cirrhosis-
related death, but not of the risk of death from other
causes (Figure 2).
Discussion
In this study of a large cohort of patients with newly-diag-
nosed cirrhosis and long-term follow-up we found that
GEC was a predictor of mortality, also after adjustment for
the effects of possible confounders, including comorbid-
ity. As expectable, it was a stronger predictor of mortality
among the 75% of patients with a decreased GEC (below
1.75 mmol/min) than among the 25% of patients with a
well preserved or normal GEC.
Our findings are consistent with the existing studies of
GEC and mortality of cirrhosis patients [6-12,26,27], but
our study extends them by being sufficiently large to
examine subgroups; by examining both cirrhosis-related
mortality and mortality from other causes; by having
complete long-term follow-up; by presenting a near-con-
tinuous relationship between GEC and short- and long-
term mortality; and by adjusting for relevant confounders.
Table 1: Impact of confounding by gender, age, and comorbidity on the association between GEC and mortality of cirrhosis patients, 
estimated with Cox proportional hazards regression.
Crude HR (95% CI) Adjusted HR (95% CI)
GEC < 1.75 mmol/min
GEC, per 0.5 mmol/min 0.74 (0.59–0.92) 0.64 (0.51–0.81)
Male vs. female 1.31 (1.06–1.63) 1.41 (1.13–1.76)
Age, per decade 1.22 (1.11–1.35) 1.20 (1.09–1.32)
Comorbidity, CCI ≥ 1 vs. 0 1.40 (1.11–1.78) 1.37 (1.08–1.75)
GEC ≥ 1.75 mmol/min
GEC, per 0.5 mmol/min 0.79 (0.59–1.05) 0.80 (0.60–1.08)
Male vs. female 1.46 (0.87–2.46) 1.44 (0.86–2.43)
Age, per decade 1.28 (1.07–1.52) 1.23 (1.02–1.48)
Comorbidity, CCI ≥ 1 vs. 0 1.59 (1.08–2.35) 1.42 (0.95–2.12)
Comorbidity is defined by the Charlson comorbidity index (CCI). Associations are expressed as hazard ratios (HR) and presented without 
adjustment (Crude HR) and with adjustment for the potential confounders.
Mortality from cirrhosis-related and not-cirrhosis related causes by GEC for the 591 cirrhosis patients who were included  before 31 December 2001 Figure 2
Mortality from cirrhosis-related and not-cirrhosis related causes by GEC for the 591 cirrhosis patients who 
were included before 31 December 2001.
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The dominance of alcoholic cirrhosis was expected [28],
since viral hepatitis is not endemic in Denmark [29,30].
Patients with alcoholic liver disease are admitted to hospi-
tal when they are ill, whereas patients with viral hepatitis
are followed in outpatient surveillance programs; there-
fore patients with alcoholic cirrhosis are more likely to
have advanced cirrhosis at the time of diagnosis. This may
explain why 75% of our patients had a decreased liver
function at the time of cirrhosis diagnosis. This character-
istic of our cohort should not detract from the generaliza-
bility of our findings, since we found the same association
between GEC and mortality in patients with alcoholic and
non-alcoholic cirrhosis.
We did not use clinical and laboratory data in the present
study because such data would primarily have been used
to substantiate the diagnosis of cirrhosis. Rather, we used
the final diagnoses reported to the National Patient Regis-
try. On a nationwide basis, about 15% of the cirrhosis
diagnoses in this registry are wrong [31], but we expect
this percentage to be markedly lower in our study because
all patients were recruited from referral centers for liver
disease with focused diagnostic work-up programs; the
large proportion of cirrhosis-related deaths supported this
assumption.
In our analyses we adjusted for gender, age, and comor-
bidity, but we cannot rule out that other confounders may
have contributed to the GEC-mortality association. How-
ever, no confounder can realistically explain the full
extent of the association.
The GEC test has not gained widespread use in clinical
hepatology despite its advantage of measuring the liver's
metabolic capacity. Likely reasons include the need for
intravenous administration of galactose, sampling of cap-
illary blood, and subsequent laboratory work, as well as
an inherent individual variability in test results of up to
10–20% by repeated measurements [32], partially due to
variation in the time course of GEC among patients [33].
Additionally, it is still uncertain whether GEC improves
the accuracy of clinical prediction rules based on clinical
data and standard blood chemistry tests to an extent that
justifies its complexity [6-12]. The present findings, how-
ever, indicate that GEC may be able to transcend clinical
features of cirrhosis and deliver unconfounded and prog-
nostically meaningful information on liver function.
When such robust information is important, e.g. in critical
clinical situations involving patients with multiple com-
plications and comorbid diseases, the GEC may present a
unique basis for decisions, its inconveniences notwith-
standing.
Conclusion
Our study demonstrated the association between GEC
measured at the time of cirrhosis diagnosis and all-cause
and cirrhosis-related short- and long-term mortality. GEC
was a strong predictor of mortality among patients with a
decreased GEC, below 1.75 mmol/min, and a weak pre-
dictor of mortality among patients with a higher GEC.
These findings are in accordance with the concept that the
total metabolic capacity of the liver is important for the
prognosis of patients with chronic liver disease.
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